Receives SFDA IND Approval and Begins Phase I Clinical Trial of Sulfatinib for the Treatment of Cancer

Shanghai: Thursday, May 6, 2010: Hutchison MediPharma had earlier announced that it has initiated the first-in-human Phase I clinical trial of its anti-cancer drug candidate, Sulfatinib, after it received approval from the regulatory authorities in China.  The investigational new drug application (“IND”) was reviewed through the State Food and Drug Administration’s (SFDA) Green Channel expedited application process.  The first patients were dosed on April 28.

Sulfatinib (HMPL-012) is a novel small molecule that selectively inhibits the tyrosine kinase activity associated with vascular endothelial growth factors (VEGFs) and fibroblast growth factor (FGF) receptors.  Pre-clinical data shows that this compound is a potent suppressor of angiogenesis, an established approach in anti-cancer treatment.  It also indicated that it is generally well tolerated in animals.  Sulfatinib was discovered and developed internally by Hutchison MediPharma.

The Phase I clinical study is being conducted in China.  The trial is an open-label, dose-escalation study.  The primary objective of the trial is to estimate the maximum tolerated dose (MTD) and assess the safety and tolerability in patients with advanced solid tumors.  The secondary objectives include the assessment of single and multiple dose pharmacokinetics and the evaluation of Sulfatinib’s antitumor activity.

Dr. Samantha Du, Chief Executive Officer of Hutchison MediPharma, said: “This clinical trial approval and its initiation mark a major achievement for the oncology R&D organization at Hutchison MediPharma.  Sulfatinib is a highly potent and selective VEGF signaling inhibitor, and we are very pleased that we have advanced this anti-cancer agent into clinical development.  There is a clear medical need for more effective and safe anti-angiogenic treatments for cancer.”

About the Vascular Endothelial Growth Factor in Cancer Tumors

Angiogenesis, the process of developing new blood vessels, is critical for tumor cell growth, survival, invasion and metastasis.  The vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFRs) play a pivotal role in tumor-related angiogenesis, and the VEGF/VEGFR pathway is an important target for anti-angiogenic drug development and tumor therapy.  Inhibition of VEGF signaling in tumor vasculature therefore represents an exciting therapeutic strategy, with the potential to arrest the development of new blood vessels essential for tumor growth and metastasis.  Several anti-VEGF agents have shown efficacy in a range of tumor types.

Sulfatinib is a potent, selective, small molecule tyrosine kinase inhibitor of VEGFs.  In vivo, Sulfatinib inhibited the growth of multiple human tumors xenografts in mice.

About Hutchison MediPharma

Hutchison MediPharma is a leading biotechnology company in China.  It has a team of well over 200 scientists and staff focusing on discovery and development of botanical drugs, semi-synthetic natural product drugs, and synthetic single chemical entity drugs.  Hutchison MediPharma has a pipeline of single new chemical entity projects in both oncology and auto-immune/inflammatory disease.

Hutchison MediPharma Limited
Building 4, 720 Cailun Road
Zhangjiang Hi-Tech Park
Shanghai 201203
China

Tel: +86 21 5079 0088
Fax: +86 21 5079 3900
Email: BD@hmplglobal.com
Website: www.hmplglobal.com